Mark Atkinson

A-Mark Precious Metals Closes Previously Announced Purchase of Minority Interest in United Kingdom-Based Atkinsons Bullion & Coins

Retrieved on: 
Thursday, May 25, 2023
Calendar, Mark Atkinson, A-Mark Precious Metals, Metal, Cryptocurrency, Atkinsons

EL SEGUNDO, May 25, 2023 (GLOBE NEWSWIRE) -- A-Mark Precious Metals, Inc. (NASDAQ: AMRK) (A-Mark), a leading fully integrated precious metals platform, today announced that it has closed its previously reported agreement to purchase a 25% ownership interest in the parent company of Atkinsons Bullion & Coins (“Atkinsons”).

Key Points: 
  • EL SEGUNDO, May 25, 2023 (GLOBE NEWSWIRE) -- A-Mark Precious Metals, Inc. (NASDAQ: AMRK) (A-Mark), a leading fully integrated precious metals platform, today announced that it has closed its previously reported agreement to purchase a 25% ownership interest in the parent company of Atkinsons Bullion & Coins (“Atkinsons”).
  • Founded in 1990, Atkinsons, which reported revenue of over $130 million in calendar 2022, is a leading United Kingdom-based online retailer of precious metals, bullion and coins.
  • In connection with the agreement, A-Mark received an option, exercisable starting in May 2025, to acquire an additional 24.5% ownership interest in Atkinsons, which, if exercised, would increase A-Mark’s ownership interest to 49.5%.
  • “A-Mark has been working closely with the Atkinsons team since we announced our proposed investment in February.

A-Mark Precious Metals to Purchase Minority Interest in United Kingdom-Based Atkinsons Bullion & Coins

Retrieved on: 
Friday, February 3, 2023
Calendar, Metal, Partnership, DTC, Mark Atkinson, Direct, A-Mark Precious Metals, Cryptocurrency, Atkinsons

Founded in 1990, Atkinsons is a leading United Kingdom-based online retailer of precious metals, bullion and coins.

Key Points: 
  • Founded in 1990, Atkinsons is a leading United Kingdom-based online retailer of precious metals, bullion and coins.
  • In connection with the agreement, A-Mark and Atkinsons will enter into a three-year supplier agreement which includes a renewal provision.
  • A-Mark will also be granted an option, exercisable no sooner than 24 months after the closing, to purchase an additional 24.5% ownership interest in Atkinsons which, if exercised, would increase A-Mark’s ownership interest to 49.5%.
  • “The A-Mark team and I are impressed with Atkinsons’ track record within its Direct-to-Consumer (DTC) market,” said A-Mark CEO Greg Roberts.

Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting

Retrieved on: 
Monday, February 22, 2021
Medical specialties, Immunology, Medicine, Clinical medicine, Immune system, Clusters of differentiation, Programmed cell death protein 1, Autoimmune disease, Mark Atkinson, Autoimmunity, Immunomodulation, Type 1 diabetes

PD-1 is an inhibitory receptor located on conventional T cells, which, when activated, promotes the attenuation of an immune attack.

Key Points: 
  • PD-1 is an inhibitory receptor located on conventional T cells, which, when activated, promotes the attenuation of an immune attack.
  • With tissue-tethered immunomodulation, were able to increase locally the concentration of our therapeutic candidates, driving robust responses in animal models that are not possible with their untethered counterparts.
  • The data presented at nPOD give us confidence in pursuing a tissue-tethered approach for T1D and other autoimmune diseases of the pancreas in collaboration with JDRF and Astellas.
  • Pandion Therapeuticsis developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.

JDRF Canada is marking National Diabetes Awareness Month by asking those impacted to write a letter to type 1 diabetes with the launch of their "Dear Type 1" Campaign

Retrieved on: 
Tuesday, November 10, 2020
JDRF, Organ systems, Health, Diabetes, Clinical medicine, Juvenile Diabetes Cure Alliance, Mark Atkinson

TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- JDRF Canada, the leading organization funding type 1 diabetes(T1D) research, is marking National Diabetes Awareness Month (NDAM) by honouring the power and resilience of the T1D community with the Dear Type 1 campaign.

Key Points: 
  • TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- JDRF Canada, the leading organization funding type 1 diabetes(T1D) research, is marking National Diabetes Awareness Month (NDAM) by honouring the power and resilience of the T1D community with the Dear Type 1 campaign.
  • As we continue to navigate the COVID-19 pandemic, we cannot let research and support for those living with type 1 diabetes slow down.
  • November is National Diabetes Awareness Month, which is celebrated across the world as a month to educate and raise awareness about the disease.
  • JDRF is the leading global organization funding type 1 diabetes (T1D) research.

Help Eliminate All Diabetes – Let’s Cure It

Retrieved on: 
Thursday, November 5, 2020
Organ systems, Health, Diabetes, Disability, Clinical medicine, Mark Atkinson

Cure diabetes by 2022, one $22 donation at a time.

Key Points: 
  • Cure diabetes by 2022, one $22 donation at a time.
  • Since then, treatments for diabetes have come a long way but treatment is not enough.
  • He feels that a concentrated effort will put a cure for diabetes within reach.
  • On World Diabetes Day, lets honor Dr. Banting and his team by taking their groundbreaking work to the next level lets move from treating diabetes to curing it.

Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2

Retrieved on: 
Wednesday, September 16, 2020
Clinical medicine, RTT, Medicine, Organ systems, Mark Atkinson, Diamyd Medical, Immunotherapy, Diabetes, Type 1 diabetes, Insulin, Diamyd

In connection to this, CEO Ulf Hannelius together with the trial'sCoordinating Investigator Professor Johnny Ludvigsson and Professor Mark Atkinson will hold a webcast presentation on Thursday 17 September at 15.00 CET.

Key Points: 
  • In connection to this, CEO Ulf Hannelius together with the trial'sCoordinating Investigator Professor Johnny Ludvigsson and Professor Mark Atkinson will hold a webcast presentation on Thursday 17 September at 15.00 CET.
  • Diamyd Medical develops therapies for type 1 diabetes.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2

Retrieved on: 
Wednesday, September 16, 2020
Clinical medicine, RTT, Medicine, Organ systems, Mark Atkinson, Diamyd Medical, Immunotherapy, Diabetes, Type 1 diabetes, Insulin, Diamyd

In connection to this, CEO Ulf Hannelius together with the trial'sCoordinating Investigator Professor Johnny Ludvigsson and Professor Mark Atkinson will hold a webcast presentation on Thursday 17 September at 15.00 CET.

Key Points: 
  • In connection to this, CEO Ulf Hannelius together with the trial'sCoordinating Investigator Professor Johnny Ludvigsson and Professor Mark Atkinson will hold a webcast presentation on Thursday 17 September at 15.00 CET.
  • Diamyd Medical develops therapies for type 1 diabetes.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Medtronic Gives $1 Million in Product Donations to Insulin for Life to Support COVID-19 Relief Efforts

Retrieved on: 
Thursday, April 30, 2020
Medicine, Clinical medicine, Eli Lilly and Company, Organ systems, RTT, Medtronic, Insulin, Diabetes, Mark Atkinson

Insulin for Life USA is a non-profit that supports continuity of therapy for people living with diabetes who otherwise would go without these critical and often life-saving supplies.

Key Points: 
  • Insulin for Life USA is a non-profit that supports continuity of therapy for people living with diabetes who otherwise would go without these critical and often life-saving supplies.
  • Our hearts go out to all those who are suffering losses due to this pandemic.
  • We are encouraging customers that need this additional support to leverage the flexible payment plans and financial assistance programs we offer, said Salmon.
  • Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries.

Thousands of cyclists come together to find a cure for type 1 diabetes at Yonge-Dundas Square

Retrieved on: 
Wednesday, October 9, 2019
JDRF, Diabetes, Health, Medicine, Clinical medicine, Juvenile Diabetes Cure Alliance, Mark Atkinson

JDRF is the leading global organization funding type 1 diabetes research.

Key Points: 
  • JDRF is the leading global organization funding type 1 diabetes research.
  • Our goal is to raise funds to support the most advanced international type 1 diabetes research and progressively remove the impact of this disease from peoples lives until we achieve a world without type 1 diabetes.
  • JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure type 1 diabetes.
  • JDRF is the largest charitable funder of and advocate for research to cure, prevent and treat T1D in the world.

People With Diabetes Impacted By Hurricane Florence: National Diabetes Coalition Available To Support

Retrieved on: 
Friday, September 14, 2018
Diabetes, RTT, American Diabetes Association, Prediabetes, Diabetes mellitus, Health, Medicine, Clinical medicine, Mark Atkinson, Epidemiology of diabetes mellitus

The Diabetes Disaster Response Coalition (DDRC) formed in 2017 in response to a succession of devastating Atlantic hurricanes that impacted the mainland US and territories.

Key Points: 
  • The Diabetes Disaster Response Coalition (DDRC) formed in 2017 in response to a succession of devastating Atlantic hurricanes that impacted the mainland US and territories.
  • Nearly half of American adults have diabetes orprediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S.
  • Founded in 1940, the American Diabetes Association (ADA) is the nation's leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes.
  • Find us on Facebook ( American Diabetes Association ), Twitter ( @AmDiabetesAssn ) and Instagram ( @AmDiabetesAssn )
    JDRF is the leading global organization funding type 1 diabetes (T1D) research.